Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.
Herpes Simplex Virus Type 1 (HSV-1) infection is widespread and causes significant disease. A number of prophylactic vaccine strategies have elicited protective immunity in animal models, but no human vaccine has yet been effective. Asymptomatic HSV-1 infection is common, demonstrating that the immune system is able to control infection, despite failure to clear the virus. Therefore, therapeutic vaccination may be a viable strategy against HSV-1. This review will discuss the epidemiology, molecular biology, and immune response to HSV-1, prophylactic and therapeutic vaccine strategies, and the potential of future therapeutic HSV-1 vaccines to reduce or eliminate HSV-1 pathology.
Ferenczy
Michael W
MW
Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA. mwf5@pitt.edu
D000818:Animals; D006561:Herpes Simplex / Q000276:immunology / Q000517:prevention & control*; D022301:Herpes Simplex Virus Vaccines / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D018139:Simplexvirus / Q000276:immunology*; D013678:Technology, Pharmaceutical / Q000639:trends*
D022301:Herpes Simplex Virus Vaccines